Gouty arthritis
Conditions
Interventions
The simple uric acid-lowering drug treatment group (control group):Simple treatment with uric acid-lowering drugs
Arthroscopic cleaning combined with uric acid-lowering drug treatment group (experimental group):Arthroscopic decontamination combined with uric acid-lowering drug treatment
Sponsors
Peking University Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.According to the classification criteria of gouty arthritis by the American College of Rheumatology/European League of Rheumatology in 2015, individuals are scored. When the score is greater than or equal to 8 points, they are classified as having gouty arthritis, and the gout attack sites are the knee and ankle joints. 2. Physical examination or imaging tests suggest the presence of tophi in one or both joint cavities of the knee or ankle, and meet one of the following imaging quantification criteria: imaging (MRI, CT or high-frequency ultrasound) indicates that the maximum diameter of the tophi is >= 5 mm; Tophi are located within the joint cavity or in the surrounding synovial tissue, and they affect the range of motion of the joint or cause limited joint movement (ROM reduction >=10°). The range of tophi can be seen in one or both knee/ankle joints. According to the location, it is recorded as "single-joint type" or "double-joint type". 3. Age between 18 and 65 years old; 4. No uric acid-lowering drugs were used for treatment within 2 weeks before the operation; 5. Complete hospitalization and follow-up data; 6. No cognitive dysfunction, able to cooperate with treatment and assessment; 7. Sign the informed consent form; 8. In the chronic gout stage or the intermission period of attacks, that is, without obvious acute symptoms such as joint redness and swelling during the study, and the condition has been stable for >=2 weeks.
Exclusion criteria
Exclusion criteria: 1.Pseudo-gout or inflammatory responses caused by other reasons; 2.Preoperative administration of glucocorticoids, anticoagulants, diuretics or other drugs that affect uric acid excretion; 3.Renal insufficiency (patients with severe renal injury or end-stage renal disease; estimated glomerular filtration rate [eGFR]<30ml/ (min*1.73^2); 4.Active peptic ulcer combined with heart disease, malignant tumor, active pulmonary tuberculosis or blood disease; 5.Those who have undergone other surgeries.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The changes in serum uric acid levels half a year after treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Imaging manifestations (CT three-dimensional reconstruction for evaluating postoperative MSU crystal deposition);Risks related to rehabilitation activities;Joint Pain Score (VAS);Knee Joint Function Score (Lysholm, WOMAC);Risks related to drug treatment;Knee joint range of motion (ROM);Surgery-related risks; | — |
Countries
China
Contacts
Public ContactXintao Zhang
Peking University Shenzhen Hospital
Outcome results
None listed